Av-101, a pro-drug antagonist at the nmda receptor glycine site, reduces l-dopa induced dyskinesias in mptp monkeys

HIGHLIGHTS

• who: Mu00e9lanie Bourque and colleagues from the Centre de Recherche du CHU de Quu00e9bec, Axe Neurosciences, Quu00e9bec, QC G V, Canada Department of Pharmacology and, University of Liverpool, Liverpool GL, UK have published the paper: AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys, in the Journal: Cells 2022, 11, x FOR PEER REVIEW of 26/09/2022
• what: The study showed antidyskinetic activity of AV-101 in MPTP monkeys was comparable to amantadine tested previously in the laboratory in this model. Evidence of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.